Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Aurinia Pharmaceuticals Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences on May 8, 2026, expanding its pharmaceutical portfolio and pipeline through a tender offer for all outstanding shares. This strategic move strengthens Aurinia's market position and growth trajectory in the biopharmaceutical sector.
Key Takeaways
Aurinia successfully completed a tender offer to acquire 100% of Kezar Life Sciences' outstanding common shares on May 8, 2026
The acquisition was executed under an Agreement and Plan of Merger dated March 30, 2026, involving Aurinia Pharma U.S., Inc. and subsidiary Aurinia Merger Sub, Inc.
2 more takeaways
Related Filings (2)
2 more filings from Aurinia Pharmaceuticals Inc. in the last 90 days